scilex
holding
company
subsidiary
sorrento
therapeutics
announces
continuous
sales
growth
expects
complete
enrollment
phase
pivotal
trial
program
preliminary
net
sales
ztlido
approximately
million
growth
compared
despite
continued
impact
pandemic
approximately
million
growth
compared
despite
continued
impact
pandemic
phase
pivotal
trial
investigating
therapy
lumbosacral
radicular
pain
sciatica
enrolled
data
expected
announced
despite
ongoing
pandemic
delayed
put
hold
hundreds
clinical
trials
around
world
could
potentially
first
fda
approved
epidural
steroid
product
treatment
sciatica
potential
replace
current
million
epidural
steroid
injections
administered
year
palo
alto
globe
newswire
scilex
holding
company
scilex
subsidiary
sorrento
therapeutics
nasdaq
srne
sorrento
today
announced
continuous
sales
growth
quarter
quarter
scilex
expects
third
quarter
net
sales
grow
approximately
compared
preliminary
third
quarter
net
sales
information
presented
press
release
based
scilex
current
expectations
may
adjusted
result
among
things
completion
customary
quarterly
review
procedures
scilex
currently
evaluated
pivotal
phase
clinical
trial
evaluate
patients
lumbosacral
radicular
pain
sciatica
trial
expected
complete
enrollment
fourth
quarter
data
expected
second
quarter
scilex
intends
use
results
pivotal
phase
trial
discuss
health
authorities
basis
licensure
application
food
drug
administration
fda
high
unmet
need
indication
treatments
approved
responsible
millions
people
suffering
alone
scilex
extensive
clinical
data
including
multiple
phase
clinical
trials
novel
viscous
formulation
designed
provide
extended
local
effect
sciatica
patients
robust
data
collected
course
company
clinical
development
program
presented
fda
part
new
drug
application
clear
corticosteroid
lumbar
epidural
analgesia
radiculopathy
clinical
study
randomized
phase
trial
expected
enroll
patients
lumbosacral
radicular
pain
sites
across
primary
endpoint
study
mean
change
numeric
pain
rating
scale
nprs
leg
pain
epidural
injection
compared
intramuscular
injection
placebo
four
weeks
secondary
endpoints
include
measures
pain
weeks
well
time
repeat
injection
safety
function
study
includes
extension
build
safety
database
patients
treated
anxiously
awaiting
new
injectable
formulation
dexamethasone
registration
treatment
radicular
pain
based
results
large
randomized
trial
approved
fda
would
first
corticosteroid
epidural
injections
addressing
safety
issues
steroid
medications
currently
used
important
addition
armamentarium
interventional
pain
physicians
said
steve
cohen
chief
pain
medicine
professor
anesthesiology
critical
care
medicine
neurology
physical
medicine
rehabilitation
johns
hopkins
school
medicine
professor
anesthesiology
physical
medicine
rehabilitation
walter
reed
national
military
medical
center
uniformed
services
university
health
sciences
novel
injectable
viscous
gel
formulation
development
treatment
lumbosacral
radicular
pain
containing
neurotoxic
preservatives
surfactants
solvents
particulates
formulation
administered
epidural
injection
based
preclinical
clinical
studies
conducted
date
extends
residency
time
site
injection
demonstrated
safety
concerns
led
fda
issue
class
warning
currently
use
injectable
corticosteroids
include
information
risk
serious
neurologic
events
epidural
steroid
injections
esis
lumbosacral
radicular
pain
otherwise
known
sciatica
commonly
treated
epidural
steroid
injections
estimated
ten
eleven
million
epidural
steroid
injections
administered
per
year
alone
approved
steroids
epidural
clinical
results
pivotal
phase
trial
seminal
milestone
scilex
may
provide
encouraging
news
many
millions
people
confronting
debilitating
radicular
pain
sciatica
believe
could
first
epidural
steroid
product
patients
suffering
common
painful
condition
said
jaisim
shah
president
chief
executive
officer
scilex
overall
estimated
number
esi
procedures
million
across
medicare
private
coverage
patients
lumbar
radiculopathy
sciatica
procedures
comprising
approximately
esis
administered
despite
widespread
utilization
esis
concerns
persist
market
particulate
steroids
potential
side
effect
safety
concerns
stroke
current
use
result
significant
unmet
medical
need
exists
within
market
potent
esi
formulation
demonstrated
safety
effectiveness
controlled
clinical
trial
million
people
live
low
back
radicular
pain
population
expected
grow
population
many
patients
experience
moderate
severe
pain
intolerance
inadequate
response
current
analgesic
therapies
opioids
nonsteroidal
drugs
nsaids
great
need
highly
effective
analgesic
medications
provide
patient
relief
without
toxicity
tolerability
challenges
nsaids
opioid
prescriptions
account
percent
chronic
pain
market
carry
risk
abuse
misuse
underscoring
need
alternative
pain
therapies
without
medical
societal
chronic
pain
affects
million
almost
nearly
million
patients
suffering
lower
back
pain
costs
united
states
approximately
billion
government
agencies
physicians
patients
payers
looking
alternatives
opioids
reduce
risk
dependency
addiction
serious
side
effects
respiratory
depression
constipation
still
offering
potent
solutions
people
living
chronic
pain
sorrento
therapeutics
sorrento
clinical
stage
biopharmaceutical
company
developing
new
therapies
treat
cancers
sorrento
multimodal
multipronged
approach
fighting
cancer
made
possible
extensive
platforms
including
key
assets
fully
human
antibodies
library
clinical
stage
therapies
conjugates
adcs
clinical
stage
oncolytic
virus
sorrento
also
developing
potential
antiviral
therapies
vaccines
coronaviruses
including
diagnostic
test
solutions
including
sorrento
commitment
therapies
patients
also
demonstrated
effort
advance
agonist
pain
management
small
molecule
resiniferatoxin
rtx
lidocaine
topical
system
treatment
neuralgia
rtx
completed
phase
trial
intractable
pain
associated
cancer
phase
trial
osteoarthritis
patients
approved
fda
february
undergoing
phase
pivotal
trial
treatment
lumbosacral
radicular
pain
sciatica
information
visit
scilex
holding
company
scilex
holding
company
subsidiary
sorrento
therapeutics
nasdaq
srne
pain
management
company
focused
development
commercialization
topical
injectable
therapies
scilex
targets
indications
high
unmet
needs
large
market
opportunities
therapies
treatment
patients
moderate
severe
chronic
pain
scilex
launched
first
commercial
product
october
developing
pipeline
includes
pivotal
phase
candidate
phase
candidate
commercial
product
lidocaine
topical
system
ztlido
prescription
lidocaine
topical
product
approved
food
drug
administration
relief
pain
associated
postherpetic
neuralgia
form
nerve
pain
scilex
two
product
candidates
mg
dexamethasone
sodium
phosphate
viscous
gel
phase
novel
viscous
gel
formulation
widely
used
corticosteroid
epidural
injections
treat
lumbosacral
radicular
pain
sciatica
lidocaine
topical
system
phase
formulation
ztlido
treatment
chronic
low
back
pain
statements
press
release
statements
made
presentation
meeting
concerning
matters
discussed
press
release
contain
statements
related
sorrento
therapeutics
subsidiaries
including
limited
scilex
holding
company
scilex
pharmaceuticals
semnur
pharmaceuticals
safe
harbor
provisions
section
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
statements
regarding
expected
timing
completing
enrollment
phase
trial
expected
third
quarter
net
sales
expected
timing
receipt
data
phase
trial
discussions
fda
health
authorities
regarding
new
drug
application
clinical
trial
endpoints
expectations
may
first
epidural
steroid
product
treatment
sciatica
outcome
data
clinical
trial
scilex
holding
prospects
future
clinical
trials
results
thereof
market
patient
population
trends
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
statements
include
limited
risks
related
completion
customary
quarterly
financial
statement
review
procedures
clinical
development
risks
including
risks
progress
timing
cost
results
clinical
trials
product
development
programs
risks
prior
test
study
trial
results
may
replicated
future
studies
trials
risks
may
meet
endpoints
clinical
study
data
may
support
nda
submission
risks
difficulties
delays
obtaining
regulatory
approvals
risks
related
global
impact
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
may
required
law
media
investor
relations
alexis
nahama
svp
corporate
development
telephone
email
mediarelations
website
sorrento
logo
registered
trademarks
sorrento
therapeutics
trademarks
sorrento
therapeutics
trademark
owned
scilex
pharmaceuticals
trademarks
property
respective
owners
sorrento
therapeutics
rights
reserved
references
syneos
health
consulting
syneos
leading
management
consulting
firm
specializing
life
sciences
industry
nejm
july
editorial
epidural
glucocorticoid
injections
patients
lumbar
spinal
stenosis
gunnar
andersson
institute
medicine
national
center
health
statistics
datamonitor
december
decisions
resources
group
chronic
pain
disease
landscape
forecast
decisions
resources
group
chronic
pain
disease
landscape
forecast
decisions
resources
group
chronic
pain
disease
landscape
forecast
decisions
resources
group
chronic
pain
disease
landscape
forecast
decisions
resources
group
chronic
pain
disease
landscape
forecast
nih
report
david
reuben
anika
alvanzo
takamaru
ashikaga
anne
bogat
christopher
callahan
victoria
ruffing
david
steffens
national
institutes
health
pathways
prevention
workshop
role
opioids
treatment
chronic
pain
annals
internal
medicine
doi
decision
resources
group
